By: IPP Bureau
Last updated : October 30, 2025 10:21 am
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Roche has received CE mark for its Elecsys Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection. This milestone promises to set a new standard for efficiency and reliability in tackling the growing global challenge of dengue fever.
The symptoms of dengue aren't unique, so doctors often struggle to distinguish it from other fever-causing illnesses, such as chikungunya or yellow fever. This is why early and accurate diagnosis is critical so that patients can be managed in a timely manner to prevent severe complications.
“Dengue’s rapid worldwide spread has elevated it to a serious global burden, placing a significant strain on healthcare resources,” said Matt Sause, CEO of Roche Diagnostics. “Roche is committed to supporting the global response to the rise of infectious diseases such as dengue. With our novel Elecsys Dengue antigen test, we enable healthcare systems to diagnose dengue more reliably and efficiently.”
Recognising the value of diagnostics, the World Health Organization (WHO) has developed an “Essential Diagnostics List” which includes in-vitro diagnostic solutions that should be accessible to all countries to increase timely and life-saving diagnoses. Dengue virus NS1 antigen, along with other biomarkers, is included in the WHO essential IVD list.